Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients

Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.

Source: Cancer Biotherapy and Radiopharmaceuticals - March 25, 2024 Category: Cancer & Oncology Authors: Yibo Chen Tianyi Zhang Rui Zhang Xuchen Cao Source Type: research